MX342539B - Nuevos radioinmunoconjugados y usos de estos. - Google Patents

Nuevos radioinmunoconjugados y usos de estos.

Info

Publication number
MX342539B
MX342539B MX2015000391A MX2015000391A MX342539B MX 342539 B MX342539 B MX 342539B MX 2015000391 A MX2015000391 A MX 2015000391A MX 2015000391 A MX2015000391 A MX 2015000391A MX 342539 B MX342539 B MX 342539B
Authority
MX
Mexico
Prior art keywords
radioimmunoconjugates
present
radioimmunoconjugate
cancer
aspects
Prior art date
Application number
MX2015000391A
Other languages
English (en)
Inventor
H Larsen Roy
Dahle Jostein
S Bruland Øyvind
Original Assignee
Nordic Nanovector As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Nanovector As filed Critical Nordic Nanovector As
Publication of MX342539B publication Critical patent/MX342539B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un radioinmunoconjugado que se une a CD37 humano, caracterizado porque comprende: a) un anticuerpo anti-CD37 que comprende una cadena pesada de inmunoglobulina y una cadena ligera de inmunoglobulina, en donde la cadena pesada comprende la SEQ ID NO: 2 y la cadena ligera comprende la SEQ ID NO: 4; b) un conector quelante; y c) un radionúclido seleccionado del grupo que consiste en 177Lu, 212Pb, 225Ac, 227Th y 90Y.
MX2015000391A 2010-01-29 2011-01-28 Nuevos radioinmunoconjugados y usos de estos. MX342539B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29952410P 2010-01-29 2010-01-29
NO20100143A NO331080B1 (no) 2010-01-29 2010-01-29 Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
PCT/EP2011/051231 WO2011092295A2 (en) 2010-01-29 2011-01-28 Novel radioimmunoconjugates and uses thereof

Publications (1)

Publication Number Publication Date
MX342539B true MX342539B (es) 2016-10-04

Family

ID=44319900

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012008695A MX2012008695A (es) 2010-01-29 2011-01-28 Nuevos radioinmunoconjugados y usos de estos.
MX2015000391A MX342539B (es) 2010-01-29 2011-01-28 Nuevos radioinmunoconjugados y usos de estos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012008695A MX2012008695A (es) 2010-01-29 2011-01-28 Nuevos radioinmunoconjugados y usos de estos.

Country Status (26)

Country Link
US (2) US8628749B2 (es)
EP (2) EP2528627B1 (es)
JP (2) JP5646652B2 (es)
KR (2) KR101758409B1 (es)
CN (2) CN102762230B (es)
AU (1) AU2011209441B2 (es)
BR (1) BR112012018843B8 (es)
CA (1) CA2786655C (es)
DK (2) DK2528627T3 (es)
ES (2) ES2469140T3 (es)
HK (2) HK1179157A1 (es)
HR (1) HRP20140538T1 (es)
IL (2) IL221091A (es)
MX (2) MX2012008695A (es)
NO (1) NO331080B1 (es)
NZ (1) NZ601055A (es)
PH (1) PH12017501038A1 (es)
PL (1) PL2528627T3 (es)
PT (1) PT2528627E (es)
RS (1) RS53346B (es)
RU (2) RU2560587C9 (es)
SG (1) SG182685A1 (es)
SI (1) SI2528627T1 (es)
UA (1) UA108631C2 (es)
WO (1) WO2011092295A2 (es)
ZA (1) ZA201205007B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2658438C2 (ru) * 2011-12-13 2018-06-21 Нордик Нановектор Аса Химерное терапевтическое антитело нн1 против cd-37
KR20140143810A (ko) * 2012-03-30 2014-12-17 이뮤노젠 아이엔씨 Cd37 기반 치료의 효과를 증대시키는 방법
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
ES2662964T3 (es) * 2013-06-07 2018-04-10 Nordic Nanovector Asa Terapia de combinación que comprende rituximab y el anticuerpo monoclonal HH1 radiomarcado
KR20160060634A (ko) * 2013-08-01 2016-05-30 어젠시스 인코포레이티드 Ｃｄ37 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
US10548989B2 (en) * 2015-04-07 2020-02-04 Memorial Sloan Kettering Cancer Center Nanoparticle immunoconjugates
GB201600328D0 (en) 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
JP2019529433A (ja) * 2016-09-16 2019-10-17 ノルディック ナノベクター アルメン アクスイェ セルスカプ リロトマブおよび１７７Ｌｕ‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法
KR102406510B1 (ko) 2017-07-03 2022-06-10 현대자동차주식회사 연료전지 시스템용 수소 공급 방법
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
CN111372613A (zh) * 2017-11-22 2020-07-03 诺帝克纳诺维科特公司 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
WO2023057583A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1
CN114081969A (zh) * 2021-11-23 2022-02-25 成都纽瑞特医疗科技股份有限公司 标记的小分子抗体、及其标记方法和应用
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CN101130078A (zh) * 2000-04-25 2008-02-27 拜奥根Idec公司 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗
EP1569690B1 (en) * 2002-12-13 2011-07-27 Mitra Medical Technology AB Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
JP4874090B2 (ja) * 2003-01-31 2012-02-08 イミューノメディクス、インコーポレイテッド 治療薬および診断薬を投与するための方法および組成物
US7259249B2 (en) * 2003-12-01 2007-08-21 Immunomedics, Inc. Method for preparing conjugates of proteins and chelating agents
RS54088B1 (en) 2005-07-25 2015-10-30 Emergent Products Development Seattle Llc B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37

Also Published As

Publication number Publication date
BR112012018843A8 (pt) 2017-12-19
PL2528627T3 (pl) 2014-08-29
CN102762230B (zh) 2014-08-13
RU2560587C9 (ru) 2015-11-27
KR101893720B1 (ko) 2018-08-30
DK2528627T3 (da) 2014-05-12
CN102762230A (zh) 2012-10-31
KR20130028051A (ko) 2013-03-18
PT2528627E (pt) 2014-06-12
CN104338154A (zh) 2015-02-11
US20120301396A1 (en) 2012-11-29
EP2705857B1 (en) 2016-06-22
CA2786655C (en) 2016-12-13
DK2705857T3 (en) 2016-08-29
BR112012018843B8 (pt) 2020-12-22
IL221091A (en) 2015-03-31
IL221091A0 (en) 2012-09-24
EP2705857A2 (en) 2014-03-12
JP2015057415A (ja) 2015-03-26
CA2786655A1 (en) 2011-08-04
ES2469140T3 (es) 2014-06-17
ES2592402T3 (es) 2016-11-30
JP5855209B2 (ja) 2016-02-09
HRP20140538T1 (hr) 2014-07-18
EP2528627B1 (en) 2014-03-19
CN104338154B (zh) 2017-09-22
ZA201205007B (en) 2013-09-25
AU2011209441A1 (en) 2012-07-19
RU2012135430A (ru) 2014-03-10
HK1195736A1 (zh) 2014-11-21
KR20170084349A (ko) 2017-07-19
AU2011209441B2 (en) 2016-03-03
WO2011092295A2 (en) 2011-08-04
NO20100143A1 (no) 2011-08-01
NZ601055A (en) 2013-12-20
RU2560587C2 (ru) 2015-08-20
PH12017501038B1 (en) 2017-12-11
IL237507A0 (en) 2015-04-30
US20140147384A1 (en) 2014-05-29
BR112012018843B1 (pt) 2020-09-24
EP2528627A2 (en) 2012-12-05
PH12017501038A1 (en) 2017-12-11
HK1179157A1 (en) 2013-09-27
SI2528627T1 (sl) 2014-08-29
RU2664475C1 (ru) 2018-08-17
SG182685A1 (en) 2012-08-30
KR101758409B1 (ko) 2017-07-14
MX2012008695A (es) 2012-11-23
US8628749B2 (en) 2014-01-14
BR112012018843A2 (pt) 2017-10-17
JP5646652B2 (ja) 2014-12-24
NO331080B1 (no) 2011-09-26
WO2011092295A3 (en) 2011-11-24
EP2705857A3 (en) 2014-07-30
JP2013518086A (ja) 2013-05-20
UA108631C2 (xx) 2015-05-25
RS53346B (en) 2014-10-31
US9358309B2 (en) 2016-06-07

Similar Documents

Publication Publication Date Title
PH12017501038A1 (en) Novel radioimmunoconjugates and uses thereof
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MX2020012426A (es) Anticuerpos anti-cd38.
IL225471B (en) Preparations for the prevention and treatment of cancer
GB201118656D0 (en) New compounds
MX2011003473A (es) Composiciones para el cuidado bucal.
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EP2528603A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS
ZA201206302B (en) Tooth whitening composition
IL251083A0 (en) Compounds and preparations for the treatment of cancer
MX366368B (es) Metodos para el cuidado oral prebiotico usando un sacarido.
MX2012006434A (es) Procesos para la preparacion de deferasirox, y polimorfos de deferasirox.
EP2601930A4 (en) MEANS FOR INCREASING A BLEACHING EFFECT AND APPLYING THEREOF
EP3406242B8 (en) Tlr4 antagonist for use in the treatment of increased ammonia plasma levels
GB201317815D0 (en) Oral supplementation for the reversal of human hair canities
PH12015501147A1 (en) Synbiotic composition and use thereof
MX2013008559A (es) Derivados de leptina.
MX2014003264A (es) Uso cosmetico de hesperidina o un derivado de la misma en la prevencion y/o el tratamiento del olor corporal.
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists
IL222623A (en) Preparations and kits for medical treatment
EP2575766A4 (en) NEW PHARMACEUTICAL COMPOUNDS
HU1000559D0 (en) Pharmaceutical compositions for the treatment of osteoporosis and cancer
GEP20135760B (en) Medication for treating highmoritis and frontitis